復星醫藥(02196.HK)子公司通過美國FDA現場檢查

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

復星醫藥(02196.HK)子公司通過美國FDA現場檢查

阿思達克 10-31 01:26

復星醫藥(02196.HK)公布，控股子公司桂林南藥通過美國食品藥品監督管理局(FDA)現場檢查，涉及產品包括鹽酸舍曲林片、復方磺胺甲噁唑片、原料藥(布美他尼)。本次檢查涉生產設施為現有口服制劑生產製造中心的OSD-I車間和原料藥生產製造中心的API-II車間，其中，OSD-I車間首次通過美國FDA現場檢查。

復星醫藥(02196.HK)

Relevant Stocks

復星醫藥(02196.HK)

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

復星醫藥(02196.HK)子公司通過美國FDA現場檢查

Services

About Us

Agreement Statement